Follow the Pundits
Tag: HedgeFunds
Ackman IPO: Genius Play or Structural Trap? 🎩📉
Bill Ackman is opening the gates to his investing empire—but is this IPO a golden ticket or a cleverly packaged trade-off? From NAV discounts to DIY replication, here’s the real audit behind the hype.
🏰 The $387 Billion Macro-Machine: Inside Fisher Investments (2026 Edition)
Fisher Investments doesn’t start with stocks—it starts with the world. With $387B under management, this macro-first powerhouse takes a very different approach to investing. Here’s what’s really going on under the hood.
Biotech Hedge Fund Extraordinaire Baker Bros. Advisors LP Adds To Its Stake in Madrigal Pharmaceuticals (MDGL): Should You Buy?
When the Baker Bros. — biotech’s most famous hedge fund — start scooping up more shares of Madrigal Pharma (MDGL), you know something’s cooking. With Rezdiffra sales booming, losses shrinking, and Wall Street titans circling, the tune of this Madrigal might be worth humming 🎶.
Paul Tudor Jones Loves IWM. Should You?
Paul Tudor Jones is going heavy on small caps—and maybe prepping for AI-induced doom. With 1,350+ positions and an options playbook that could fill a library, what’s his real bet? And more importantly: should you follow? Read on, but don’t YOLO.
🎶 Paul Singer of Elliott Investment Management L.P. Never Sings Out of Tune
With a $72.7B AUM symphony, Paul Singer’s Elliott Investment Management conducts activist investing like a maestro — dissonance included. Here's why their sharp portfolio and sharper strategy deserve your attention (and maybe your applause). 🎻📈